Risk Partners Life Sciences Roundtable 2025, thank you very much! 

Contact us

We congratulate Formycon AG on its successful uplisting to the Prime Standard of Deutsche Börse on November 12, 2024!

Welcome to the Prime Standard league: A new champion of life sciences and biosimilars has successfully made the step from the scale segment. We proudly congratulate Enno Spillner, Dr. Caroline Redeker, Daniel Marquard and the entire Formycon AG team on this great success and another important milestone on their way to becoming a global champion in the biosimilars sector!

Formycon AG specializes in the development of high-quality biosimilars, which represent a cost-effective alternative to original biopharmaceutical preparations. The company demonstrates its innovative strength particularly in the field of follow-on molecules and has successfully positioned itself as one of the leading suppliers of biosimilars. With its expertise in research and development, Formycon creates access to cutting-edge biopharmaceutical products that benefit patients worldwide and has now also attracted increasing interest from international investors. As a result, the company has now been listed in the Prime Standard.  

Risk Partners acted as Capital Markets Insurance Advisor in this transaction. Our team, consisting of Florian, Franziska and Björn, supported Formycon AG during the successful uplisting process from the Scale to the Prime Standard of the Frankfurt Stock Exchange on November 12, 2024.

We are particularly pleased to contribute our specialization and expertise as an insurance broker for life sciences and capital market transactions and to accompany a "neighbor" from the Planegg/Martinsried region.

Special thanks also go to our co-broker team at Dr. Ellwanger & Kramm GmbH & Co. KG, in particular Gregor Klingeler and Frieder Lang, for the trust they have placed in us and the great cooperation. If you have a similar project in mind and would appreciate our support, please do not hesitate to contact us about the added value of RP4brokers. 

Also read our other blog posts

Being Public

Risk Partners supports successful uplisting of Formycon AG to the Prime Standard

Congratulations to Formycon AG on its successful uplisting to the Prime Standard of Deutsche Börse on November 12, 2024! Welcome to the Prime Standard league: A new champion of life sciences and biosimilars has successfully made the step from the Scale segment. We proudly congratulate Enno Spillner, Dr. Caroline Redeker, Daniel Marquard and the entire Formycon AG team on this great success and another important milestone on their way to becoming a global champion in the field of biosimilars! Formycon AG has focused on

Read more "
November 14, 2024
Being Public

Prospectus liability insurance (POSI): Risk Partners publishes for you

Risk Partners on Going Public and the capital market blog on prospectus liability insurance In recent months, we have been able to share our expertise on prospectus liability insurance with a wide audience on two renowned platforms. Here is an overview: Kapitalmarkt.blog In the article "POSI insurance - The protective vest on the capital market", we explain why prospectus liability insurance is an indispensable tool for companies becoming active on the capital market. The article shows in a practical way how such insurance not only minimizes liability risks, but also strengthens investor confidence. GoingPublic Magazine In

Read more "
December 29, 2024
Being Public

New SEC Ruling: Transatlantic convergence in dealing with cyber security incidents

Foreign Filers / Private Issuers watch out! 2023 brought further harmonization of European and US standards for cyber incident reporting. According to the SEC Ruling, all companies listed on the US stock exchange are now required to publicly report significant data security incidents to the SEC within four working days. In addition, they must outline in their annual report (10-K) their procedures for identifying and addressing material cybersecurity risks, including the role of the board of directors. Note: This rule also applies to foreign private issuers (e.g., German companies that issue a

Read more "
January 17, 2024
Management

How managers protect themselves from personal liability in the event of cyber incidents - #29Minutes by Control Risk & Risk Partners

How directors and officers protect themselves from personal liability in the event of cyber incidents - #29Minutes by Control Risk & Risk Partners Looking at our claims experience in the area of directors' and officers' liability in recent years, internal claims alleging inadequate cyber risk management and emergency management in the event of a cyber attack are unfortunately on the rise. In addition to special risk transfer solutions (cyber and CDI insurance), there are also very practical tips on how to react correctly if the worst comes to the worst. Following an exchange at a risk management conference in Q1 of this year

Read more "
November 8, 2023
Management

OLG Schleswig – Statute of Limitations for Liability Claims in the Case of Direct Claims in D&O Insurance

OLG Schleswig: Statute of limitations for liability claims in the case of direct claims in D&O insurance. There is a new, exciting verdict from the world of D&O insurance. Recently, we reported on the decision of the Higher Regional Court of Cologne in the context of the direct lawsuit. Now the Higher Regional Court of Schleswig has also made a groundbreaking decision. What was it about? The focus was on the question of the statute of limitations. However, it must be taken into account that the question of the statute of limitations in the event of a D&O claim is not trivial. On the one hand, there is the original claim for damages (statutory D&O liability

Read more "
April 24, 2024
Life Sciences

Finance Day 2024

Growth capital for biotechnology and life sciences - Finance Day 2024 A few days ago, Jutta and Florian from our team attended Finance Day 2024 at the analytica trade fair in Munich. The event once again offered exciting expert panels on current financing and capital market issues for life sciences companies. As the panels focused on three of our key consulting areas, namely life sciences, venture capital and IPOs, attending was of course a must for us as a specialist insurance broker. Our team was also very pleased to meet many of our partners and clients again.

Read more "
April 19, 2024